Evolocumab 相關新聞
Evolocumab 目前有 0 則相關新聞報導,預測適應症 20 個。
本頁整合 Evolocumab 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:...
- 證據等級:L5
- 預測適應症(20 個):
- symptomatic form of hemophilia in female carriers(99.8%)
- familial apolipoprotein C-II deficiency(99.5%)
- thrombocytopenic purpura(99.4%)
- factor XI deficiency(99.3%)
- hemophilia A with vascular abnormality(99.2%)
- disease of catalytic activity(99.1%)
- hemorrhagic disease of newborn(98.9%)
- ichthyosis, X-linked, without steroid sulfatase deficiency(98.8%)
- inherited thrombophilia(98.8%)
- disorder of other vitamins and cofactors metabolism and transport(98.8%)
- adenosine deaminase deficiency(98.8%)
- xanthomatosis (disease)(98.8%)
- esophageal varices without bleeding(98.8%)
- esophageal varices with bleeding(98.8%)
- 46,XY disorder of sexual development due to dihydrotestosterone backdoor pathway biosynthesis defect(98.7%)
- 3-hydroxyacyl-CoA dehydrogenase deficiency(98.7%)
- cholesterol catabolic process disease(98.7%)
- coagulation protein disease(98.7%)
- 46,XY disorder of sex development due to a cholesterol synthesis defect(98.6%)
- neutral lipid storage disease(98.6%)
相關新聞(0 則)
目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。